NR3C2 and Stroke: Furthermore, this group of patients was more often given angiotensin-converting-enzyme inhibitors (ACE), mineralocorticoid receptor antagonists (MRA), b-blockers, diuretics, statins, and vitamin K antagonists (VKA) due to previous stroke history and higher prevalences of cardiovascular diseases.